IRadimed Corporation
HealthcareNASDAQ:IRMD · NASDAQ Capital Market
-$2.66 today
Vol 0.17M · Avg 0.14M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$86.3M of revenue converted into $23.6M of net income for the selected period. Gross margin is 76.9% and net margin is 27.4%, showing how much revenue survives after costs and taxes. EPS is $1.83, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.8M +14.4% | $73.2M +11.7% | $65.6M +23.0% | $53.3M +27.5% | $41.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $19.5M +15.4% | $16.9M +9.7% | $15.4M +28.1% | $12.0M +23.1% | $9.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $64.3M +14.2% | $56.3M +12.3% | $50.2M +21.5% | $41.3M +28.8% | $32.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 76.7% -0.2pp | 76.9% +0.4pp | 76.5% -0.9pp | 77.4% +0.8pp | 76.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $3.0M +5.1% | $2.8M -0.9% | $2.9M +25.5% | $2.3M +19.6% | $1.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $35.2M +11.6% | $31.6M +15.7% | $27.3M +16.6% | $23.4M +15.0% | $20.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $38.2M +11.0% | $34.4M +14.1% | $30.1M +17.4% | $25.7M +15.4% | $22.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.4M +191.1% | $817.7K +6.9% | $765.2K +14.1% | $670.7K -52.3% | $1.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $30.7M +22.5% | $25.1M +11.5% | $22.5M +33.5% | $16.9M +49.9% | $11.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 36.7% +2.4pp | 34.3% -0.1pp | 34.3% +2.7pp | 31.6% +4.7pp | 26.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $26.1M +19.0% | $22.0M +9.6% | $20.0M +28.2% | $15.6M +59.2% | $9.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 31.2% +1.2pp | 30.0% -0.6pp | 30.6% +1.2pp | 29.3% +5.8pp | 23.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $2.2M +17.7% | $1.9M +220.4% | $581.9K +1571.7% | $34.8K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.2M -4.2% | $2.3M +35.7% | $1.7M +207.9% | $553.1K +2872.9% | $18.6K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $28.4M +16.8% | $24.3M +11.7% | $21.7M +34.3% | $16.2M +64.5% | $9.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 33.8% +0.7pp | 33.1% -0.0pp | 33.2% +2.8pp | 30.4% +6.8pp | 23.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.9M +16.7% | $5.0M +10.9% | $4.5M +35.6% | $3.4M +556.3% | $510.8K | $1.3B | -$1.6B | $745.2M |
| Net Income | $22.5M +16.9% | $19.2M +11.9% | $17.2M +34.0% | $12.8M +37.6% | $9.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 26.8% +0.6pp | 26.3% +0.0pp | 26.2% +2.2pp | 24.1% +1.8pp | 22.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +16.4% | $2 +11.8% | $1 +33.3% | $1 +34.2% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +16.7% | $2 +11.1% | $1 +32.4% | $1 +37.8% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $12.7M +0.4% | $12.7M +0.5% | $12.6M +0.3% | $12.6M +1.8% | $12.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $12.9M +0.6% | $12.8M +0.5% | $12.7M +0.7% | $12.6M +0.4% | $12.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AxoGen, Inc.
NASDAQ:AXGN
$2.29B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.14B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
Cronos Group Inc.
NASDAQ:CRON
$1.00B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
InMode Ltd.
NASDAQ:INMD
$817.88M
MiMedx Group, Inc.
NASDAQ:MDXG
$536.20M
Claritev Corporation
NYSE:CTEV
$526.61M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IRMD generate?
IRadimed Corporation (IRMD) reported $83.81M of revenue in fiscal 2025.
Is IRMD profitable?
IRadimed Corporation (IRMD) reported $22.48M of net income, with a net margin of 26.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.